Johnson & Johnson (JNJ)
177.20
+0.74 (0.42%)
NYSE · Last Trade: Sep 17th, 4:32 PM EDT
Detailed Quote
Previous Close | 176.46 |
---|---|
Open | 176.71 |
Bid | 177.00 |
Ask | 177.19 |
Day's Range | 176.59 - 178.51 |
52 Week Range | 140.68 - 181.16 |
Volume | 6,632,269 |
Market Cap | 465.80B |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 5.200 (2.93%) |
1 Month Average Volume | 7,710,913 |
Chart
About Johnson & Johnson (JNJ)
Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
News & Press Releases
Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.
Via Benzinga · September 17, 2025
Sunnyvale, CA – September 17, 2025 – Intuitive Surgical (NASDAQ: ISRG), the pioneer and global leader in robotic-assisted surgery, has once again demonstrated its formidable market position with a robust second-quarter 2025 earnings report. The company announced an impressive adjusted Earnings Per Share (EPS) of $2.19, significantly surpassing analyst expectations, coupled
Via MarketMinute · September 17, 2025
The financial markets find themselves in a fascinating, if precarious, dance. Despite a recent surge in stock market performance, with the S&P 500 ([SPX]) registering robust gains in recent years, underlying economic currents are flashing amber. Persistent inflationary pressures continue to gnaw at purchasing power, while a noticeable deceleration
Via MarketMinute · September 17, 2025
J&J’s Investigational Plaque Psoriasis Drug Outperforms Bristol Myers’ Sotyktu In Studystocktwits.com
Via Stocktwits · September 17, 2025
Big Pharma Eyes China: J&J And Roche Reportedly In Talks For Henlius’ Experimental Cancer Drugstocktwits.com
Via Stocktwits · September 15, 2025
Johnson & Johnson (JNJ) is a top dividend stock with a 2.91% yield, over 10 years of growth, and strong financials for reliable income.
Via Chartmill · September 17, 2025
The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites.
Via Stocktwits · September 16, 2025
The financial landscape is bracing for a turbulent 2025, as expert consensus points towards a significant uptick in market volatility. This anticipated shift, driven by a complex interplay of global policies, stubbornly high inflation, and persistent geopolitical tensions, signals a departure from recent market dynamics, demanding a proactive and adaptable
Via MarketMinute · September 16, 2025
Interest rate cuts may not decrease market volatility; discover three dividend stocks that can deliver stability, income, and growth during this fall
Via MarketBeat · September 16, 2025
Central banks worldwide, spearheaded by the U.S. Federal Reserve, are signaling a significant pivot towards monetary easing in 2025. This anticipated shift, driven by a weakening labor market and cooling inflation, is poised to reshape financial markets and investor strategies. With lower borrowing costs on the horizon, a "risk-on"
Via MarketMinute · September 16, 2025
The third quarter of 2025 has been a period of stark contrasts for the global financial markets. While major U.S. stock indices like the S&P 500 and the Dow Jones Industrial Average (DJIA) have soared to unprecedented record highs, a closer look reveals a landscape fraught with economic
Via MarketMinute · September 16, 2025
Dividend-paying growth stocks and covered call ETFs provide opportunities to generate income even in a declining stock market.
Via The Motley Fool · September 16, 2025
These three companies may have what it takes to continue to build on their strong history of dividend payments even if the economy continues to sour.
Via MarketBeat · September 15, 2025
The United States economy is facing an increasingly complex and concerning confluence of risk factors, raising the specter of a looming recession. A deteriorating labor market, persistently high inflation, and the ongoing, disruptive impact of trade tariffs are interacting in ways that significantly elevate economic uncertainty for businesses, consumers, and
Via MarketMinute · September 15, 2025
As the global economy marches into 2025, it finds itself at a critical juncture, balancing the promise of moderate growth against the persistent shadows of tenacious inflation, geopolitical instability, and evolving labor market dynamics. This year is set to be defined by a complex interplay of forces that will shape
Via MarketMinute · September 15, 2025
The U.S. economy finds itself at a crossroads, with leading financial institutions and economic forecasters presenting a varied, yet generally cautious, outlook on the probability of a recession. From machine learning algorithms to traditional yield curve models, the consensus is that while a severe downturn isn't a foregone conclusion,
Via MarketMinute · September 15, 2025
The latest U.S. employment report for August 2025 has sent a palpable chill through financial markets and economic forecasts, confirming a significant deceleration in the nation's labor market. Following a rare job contraction in June—the first monthly decline in nonfarm jobs since December 2020—the unemployment rate has
Via MarketMinute · September 15, 2025
Financial markets are currently on edge, grappling with the looming possibility of a significant shock: an unexpected decision by the Federal Reserve to forgo a widely anticipated interest rate cut in September 2025. This deviation from market consensus, which largely projects a 25-basis-point reduction, could trigger a sharp negative reaction
Via MarketMinute · September 15, 2025
As autumn leaves begin to fall, a familiar chill often descends upon the financial markets, not just in temperature but in investor sentiment. September has historically earned a notorious reputation among traders and analysts as the weakest month for equities, a phenomenon widely dubbed the "September Effect." This recurring statistical
Via MarketMinute · September 15, 2025
The S&P 500's current forward price-to-earnings (P/E) ratio, hovering around 22x, has ignited a fervent debate across financial markets. This elevated valuation metric, significantly above historical averages, is prompting investors and analysts to question whether the market is perched precariously on a speculative bubble or if a new
Via MarketMinute · September 15, 2025
The answer might surprise you.
Via The Motley Fool · September 15, 2025
The global financial landscape is currently grappling with a potent concoction of heightened market instability, pervasive policy uncertainty, and an escalating array of geopolitical events. These formidable forces are collectively reshaping investment strategies and underscoring the critical need for robust diversification and strategic hedging within portfolios. As investors navigate these
Via MarketMinute · September 12, 2025
Global financial markets in 2025 are navigating a complex landscape shaped by persistently high, or "sticky," inflation and the increasingly cautious stance of major central banks regarding interest rate adjustments. Despite initial hopes for a swift return to pre-pandemic price stability, inflation, particularly in the services sector and fueled by
Via MarketMinute · September 12, 2025
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is fundamentally altering the landscape of medical treatment and diagnostics, promising a future of more personalized, precise, and preventive medicine. At the forefront of this
Via MarketMinute · September 12, 2025
In an era defined by persistent market volatility and an ongoing search for reliable income streams, a historically potent, yet sometimes overlooked, options strategy is experiencing a significant resurgence: the covered call. As global financial markets navigate a landscape shaped by inflation concerns, fluctuating interest rates, and geopolitical uncertainties, investors
Via MarketMinute · September 12, 2025